It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims
Despite the high risk of rehospitalization for heart failure (HF) and death among patients admitted to the intensive cardiac care unit (ICCU), no accurate prediction score for these outcomes exists. We aimed to develop a risk score to predict unplanned HF hospitalization and death 1‐year post‐discharge in an unselected cohort of patients admitted to the ICCU.
Methods
Based on a national, multicentre study, we included all consecutive patients admitted to the ICCUs in 39 French centres from 7 to 22 April 2021. We randomly selected a training cohort of 21 centres (n = 1008) to develop the ICCU‐HF score and a validation cohort of eight other centres (n = 463). The primary composite outcome was unplanned hospitalization for HF and cardiovascular death at 1‐year follow‐up after discharge. Using the score, patients were stratified into three risk groups to evaluate the prognostic value.
Results
Using a least absolute shrinkage and selection operator (LASSO) regression approach, we identified seven predictors: left ventricular ejection fraction, significant valvular disease grade 2+, Killip score >1, NT‐proBNP, creatinine level, previous ventricular arrhythmia and use of inotropes during hospitalization. In 1471 patients (63 ± 15 years, 70% men), 99 (6.7%) experienced the primary outcome. The ICCU‐HF score outperformed NT‐proBNP, the strongest individual predictor (area under the curve [AUC] 0.77, 95% CI [0.71–0.83] vs. AUC 0.72, 95% CI [0.66–0.79], P = 0.008), demonstrating excellent performance with an AUC of 0.83 (95% CI: 0.77–0.89) to predict outcomes in the validation cohort. Compared with the low‐risk group, the intermediate‐risk and high‐risk groups had significantly higher risks of the composite outcome (HR 4.09, 95% CI [2.23–7.50], P < 0.001 and 12.69, 95% CI [7.02–22.95], P < 0.001), proving strong risk stratification capability of the ICCU‐HF score.
Conclusions
The ICCU‐HF score showed good performance in predicting the 1‐year risk of unplanned HF hospitalization and death in a large cohort of unselected patients admitted to the ICCU, with excellent results in the validation cohort. This score effectively stratifies patients into risk groups, enhancing its utility in clinical decision‐making.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark, Université Paris Cité, Department of Cardiology, University Hospital of Lariboisiere (Assistance Publique Hôpitaux de Paris, AP‐HP), Paris, France
2 Université Paris Cité, Department of Cardiology, University Hospital of Lariboisiere (Assistance Publique Hôpitaux de Paris, AP‐HP), Paris, France, Inserm MASCOT‐UMRS 942, University Hospital of Lariboisiere, Paris, France, MIRACL.ai laboratory, Multimodality Imaging for Research and Artificial Intelligence Core Laboratory, University Hospital of Lariboisiere (AP‐HP), Paris, France
3 Department of Cardiology, Rangueil University Hospital, Toulouse, France
4 Department of Cardiovascular Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France
5 Clinical Investigation Center (INSERM 1204), Cardiology Department, University Hospital of Poitiers, Poitiers, France
6 Department of Cardiology, University Hospital of Lille, Lille, France
7 Department of Cardiology, Rouen University Hospital, Rouen, France
8 Département de Cardiologie, Clinique Ambroise Paré, Neuilly‐sur‐Seine, France
9 Service de Cardiologie, Hôpital Henri Duffaut, Avignon, France
10 Department of Cardiology, CHU Montpellier, Montpellier, France
11 Service de Cardiologie, Centre Hospitalier de Fréjus/Saint‐Raphaël, Fréjus, France
12 Unité médico‐chirurgical de valvulopathies et cardiomyopathies, Hôpital Cardiologique Haut‐Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
13 Department of Cardiology, University Hospital of Limoges, Limoges, France
14 Intensive Cardiological Care Division, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France
15 Department of Cardiology, Caen University Hospital, Caen, France
16 Department of Cardiology, University Hospital of Brest, Brest, France
17 Department of Cardiology, Andre Gregoire Hospital, Montreuil, France
18 Service de Cardiologie, Centre Hospitalier de Chartres, Le Coudray, France
19 Department of Cardiology, Saint Antoine and Tenon Hospital, AP‐HP, Sorbonne Université, Paris, France, GRC n°22, C2MV (Complications Cardiovasculaires et Métaboliques chez les patients vivant avec le Virus de l'immunodéficience humaine), Inserm UMR_S 938, Centre de Recherche Saint‐Antoine, Paris, France
20 Department of Cardiology, Hôpital Européen Georges Pompidou, Paris, France, Université Paris‐Cité, MASCOT, Inserm, Paris, France
21 Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
22 Inserm MASCOT‐UMRS 942, University Hospital of Lariboisiere, Paris, France, Department of Anesthesia and Critical Care Medicine, Hôpital Lariboisière, Assistance Publique‐Hôpitaux de Paris, Paris, France





